HIPO
Hippo Holdings Inc.
HIPO's fundamentals are mixed, but it looks expensive: trading at 29x earnings, about four times its usual 7.7x. Its downside scenario is about seven times its upside.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
HIPO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| N/A | |
| N/A |
HIPO's revenue is currently strong, and its profitability is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like HIPO.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
HIPO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.3x | $8.14 | -78% |
| Fair | 7.7x | $9.87 | -73% |
| Expensive | 11x | $14.71 | -60% |
| Forward | 23x | $36.96 | — |
| Current | 29x | $36.96 | — |
Historical ranges are pointers, not guarantees.
HIPO's PE is in its expensive range at 29x. If earnings grow as analysts expect, today's price would be 23x next year's earnings.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
HIPO Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
HIPO has the edge over IREN on the outlook, with more favorable earnings expectations.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIPO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.58 | +23% |
| Q3 2026 | $1.29 | -65% |
| Q2 2026 | $4.73 | +$5.12 |
| Q1 2026 | $4.40 | +$6.48 |
| Q4 2025 | $2.22 | +$3.86 |
| Q3 2025 | $3.72 | +$8.89 |
| Q2 2025 | -$0.39 | +$6.68 |
| Q1 2025 | -$2.08 | +$7.96 |
| Q4 2024 | -$1.64 | +$9.94 |
HIPO has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
HIPO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $156M | +29% |
| Q2 2026 | $144.7M | +23% |
| Q1 2026 | $121.5M | +10% |
| Q4 2025 | $120.4M | +18% |
| Q3 2025 | $120.6M | +26% |
| Q2 2025 | $117.3M | +31% |
| Q1 2025 | $110.3M | +30% |
| Q4 2024 | $101.9M | +58% |
HIPO's revenue has grown year over year every quarter since late 2021: $156M last quarter, up 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | -76 points |
| Q2 2026 | 7.6% | +4.2 points |
| Q1 2026 | 5.9% | +47 points |
| Q4 2025 | 5.7% | -41 points |
| Q3 2025 | 81% | +87 points |
| Q2 2025 | 3.4% | +44 points |
| Q1 2025 | -41% | -2.7 points |
| Q4 2024 | 46% | +107 points |
HIPO has the edge over IREN on profitability, with a higher operating margin.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
HIPO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $72.2M | +330% |
| Q2 2026 | $43M | +73% |
| Q1 2026 | $8.4M | +$44.1M |
| Q4 2025 | $3.2M | +$9.7M |
| Q2 2025 | $24.8M | +$35.5M |
| Q1 2025 | -$35.7M | -303% |
| Q4 2024 | -$6.5M | +$42.4M |
| Q2 2024 | -$10.7M | +$27.6M |
HIPO has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
HIPO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +478K shares |
| 1 year | +3.9% | +1M shares |
| 3 years | +14% | +3.3M shares |
| 5 years | +21% | +4.7M shares |
| Available history | +5479% | +26.5M shares |
HIPO has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2024 | $15.6M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | $1.6M |
| Q1 2023 | $200,000 |
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
HIPO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | -8.7x | Net Cash |
HIPO has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like HIPO.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
HIPO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.3 | Neutral |
| Stochastic | 68.3 | Neutral |
HIPO's weekly RSI is 63 (neutral) and its Stochastic is 68 (neutral).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
HIPO PE vs Financial Services Sector
| Metric | HIPO | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 13x | 120% above |
| PE % | 100 | 62 | 38 pts above |
HIPO is trading at 29x earnings, a 120% premium to the Financial Services sector's median of 13x.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
HIPO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.9 | 6% above |
| 20 week MA | $32.7 | 13% above |
| 50 week MA | $29.9 | 24% above |
| 100 week MA | $29.4 | 26% above |
| 200 week MA | $22.6 | 63% above |
HIPO has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
HIPO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $296.3 | $77.3 | -74% |
| 2022 | $77.3 | $12.1 | -84% |
| 2023 | $12.1 | $9.12 | -25% |
| 2024 | $9.12 | $27.4 | +200% |
| 2025 | $27.4 | $31.3 | +14% |
| 2026 YTD | $31.3 | $37.0 | +18% |
HIPO has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.